Endoscopic Sleeve Gastroplasty (Endosleeve)

January 5, 2024 updated by: IHU Strasbourg

The endoscopic sleeve gastroplasty allows stomach size reduction through an endoluminal suture approach without any incision. It could reduce the complications associated with current surgical techniques while obtaining the target gastric restriction, weight loss, comorbidities and quality of life improvement.

The primary objective of this study is to assess weight loss after endoscopic sleeve gastroplasty in patients with morbid obesity.

Study Overview

Status

Completed

Conditions

Detailed Description

Gastric restriction is one of the fundamental principles of gastric bypass and gastric banding. Nowadays, practitioners have the possibility to reduce stomach size by merging tissues through an endoscopic endoluminal suture approach without any incision. This could reduce the complications associated with current surgical techniques while obtaining the target gastric restriction, weight loss, comorbidities and quality of life improvement.

The primary objective of this study is to assess weight loss after endoscopic sleeve gastroplasty in patients with morbid obesity according to the technique described in the literature: reduction of the gastric pouch into a sleeve structure by modification of the stomach greater curvature thanks to a plication.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Strasbourg, France, 67000
        • Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil de Strasbourg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 58 years (Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients over 18 years old requiring a treatment for morbid obesity.

Description

Inclusion Criteria:

  • Patient > 18 years old and < 60 years old
  • Patient with morbid obesity for at least 2 years
  • Patient who failed medical and diet treatment of obesity
  • Patient with no contraindication to anesthesia
  • Patient able to understand the study and to provide informed consent.

Exclusion Criteria:

  • Patient with inflammatory, tumoral or bad quality tissues at endoscopy
  • Patient with a history of gastro-intestinal inflammatory disease, stenosis or intestinal adhesions, kidney or liver failure, chronic pancreatic disease
  • Patient with a history and/or signs and/or symptoms of gastroduodenal ulcerous disease and/or progressive gastroduodenal ulcerous disease
  • Patient with an oesophageal pathology as Zenker's diverticulum, peptic oesophagitis stage 3-4, oesophageal stenosis, Barrett syndrome, oesophageal cancer, dysphagia, achalasia
  • Patient with previous bariatric, gastric or oesophageal surgery, intestinal obstruction, portal hypertension, gastro-intestinal tumors, oesophageal or gastric varices, gastroparesis
  • Patient with a severe coagulopathy (prothrombin time > 3 seconds or thrombocytic count < 50 000/mm3) or treated with heparin, coumadin, warfarin or any other anticoagulants and drugs preventing coagulation or platelet aggregation, except aspirin and nonsteroidal anti-inflammatory drugs
  • Pregnancy, breastfeeding or woman without contraception
  • Patient with a congestive heart failure, arrhythmia or unstable coronary heart disease
  • Patient using or having used diet drugs within the last 30 days or intending to use them during study follow-up
  • Patient under drug treatment within the last 3 months known to induce weight gain
  • Patient with eating disorders or uncontrolled, poorly controlled or suspected psychiatric disease
  • Patient in a poor condition according to investigator
  • Patient in exclusion period (determined by a previous study or in progress)
  • Patient with significative weight loss between date of enrollment in the study and date of procedure
  • Patient with a systemic infection the day of procedure.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Endoscopic sleeve gastroplasty
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Weight loss
Time Frame: 7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
Excess weight loss
Time Frame: 7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
Body mass index variation
Time Frame: 7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Procedure reproducibility
Time Frame: 7 days, 1 - 3 - 6 - 9 and 12 months after procedure
Absence of adverse event within 12 months after procedure.
7 days, 1 - 3 - 6 - 9 and 12 months after procedure
Comorbidities improvement
Time Frame: 7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
Improvement of hyperlipidemia, arterial hypertension, diabetes, reflux, osteoarticular disorders compared with preoperative data.
7 days, 1 - 3 - 6 - 9 - 12 - 18 and 24 months after procedure
Quality of life improvement
Time Frame: 3 - 12 - 18 and 24 months after procedure
Improvement of quality of life assessed by Moorehead-Ardelt Quality of life II questionnaire and Gastro-intestinal Quality of Life Index questionnaire.
3 - 12 - 18 and 24 months after procedure
Modification in the feeling of satiety
Time Frame: 1 - 3 - 6 - 12 - 18 and 24 months after procedure
Satiety assessed by Three Factors Eating Questionnaire - R18.
1 - 3 - 6 - 12 - 18 and 24 months after procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Silvana Perretta, MD, PhD, Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil de Strasbourg
  • Principal Investigator: Michel Vix, MD, Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil de Strasbourg

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2016

Primary Completion (Actual)

May 1, 2018

Study Completion (Actual)

May 1, 2020

Study Registration Dates

First Submitted

October 26, 2016

First Submitted That Met QC Criteria

October 26, 2016

First Posted (Estimated)

October 28, 2016

Study Record Updates

Last Update Posted (Estimated)

January 8, 2024

Last Update Submitted That Met QC Criteria

January 5, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Morbid Obesity

Clinical Trials on Endoscopic sleeve gastroplasty

3
Subscribe